spinal cord injury Archives

Neuralstem’s NSI-566 Stem Cell Therapy Confers Neurological Improvement in Spinal Cord Injury Patients with Complete Paraplegia

GERMANTOWN, Md., Jun. 4 (Korea Bizwire) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced the results from a study published in the journal Cell Stem Cell that support the potential of transplanted NSI-566, a human spinal cord-derived neural stem cell line (HSSC) to benefit patients with chronic [...]

Neuralstem Announces Publication of a Study in Nature Medicine Showing Benefits of NSI-566 in a Primate Model of Spinal Cord Injury

GERMANTOWN, Md., Mar. 13 (Korea Bizwire) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on developing novel treatments for nervous system diseases, highlighted the publication of a manuscript in Nature Medicine showing that NSI-566, Neuralstem’s lead cell therapy candidate, provided meaningful improvement in forelimb function in a non-human primate model of acute spinal cord injury. [...]